Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Study results show that treatment with Golexanolone (GR3027) for 7 days significantly reduced fatigue in test group compared to the control group (p<0.05). Further analysis shows that treatment also improved other CNS symptoms.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Results from previous clinical and pre-clinical studies strongly indicate that GR3027 (golexanolone) is able to counteract such inappropriate suppression of brain activity.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Golexanolone, a novel drug candidate that counter acts the effect of allopregnanolone on GABAA receptors, thereby restoring normal nerve signalling in the brain.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
The pregnant women will be randomized to either subcutaneous injection of tafoxiparin and standard of care or only standard of care, which is usually symptomatic treatment with anti-hypertensive drugs.
Lead Product(s): Tafoxiparin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DF01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
The primary objective of the study was to document the effect of tafoxiparin on cervical ripening measured as the degree of ripening according to an internationally established scale, the Bishop score.
Lead Product(s): Tafoxiparin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DF01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Aprea Therapeutics intends to initiate a Phase 1 clinical trial of APR-548 in MDS to expand its leadership in the development of therapeutic options for patients with p53 mutated cancers.
Lead Product(s): APR-548
Therapeutic Area: Oncology Product Name: APR-548
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Aprea Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.
Lead Product(s): Golexanolone
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020